Zacks Research Comments on Bone Biologics Q1 Earnings

Bone Biologics Corp. (NASDAQ:BBLG) – Equities researchers at Zacks Research issued their Q1 2026 EPS estimates for shares of Bone Biologics in a research report issued on Tuesday, March 3rd. Zacks Research analyst B. Sorensen anticipates that the company will earn ($0.54) per share for the quarter. The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share. Zacks Research also issued estimates for Bone Biologics’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.43) EPS and FY2027 earnings at ($1.62) EPS.

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Bone Biologics in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Bone Biologics Trading Down 2.4%

NASDAQ:BBLG opened at $1.22 on Wednesday. The stock has a market capitalization of $2.20 million, a PE ratio of -0.32 and a beta of 0.78. The firm’s 50 day moving average is $1.46 and its 200 day moving average is $1.86. Bone Biologics has a 12 month low of $1.11 and a 12 month high of $6.75.

Institutional Investors Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.30% of the company’s stock.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.